Incidence of tuberculosis infection in psoriatic patients on anti‐TNF therapy: report of a case series with 144 patients

Abstract

This is the first study to underscore the incidence of LTBI in patients with psoriasis treated with anti-TNF therapy in the Spanish population. We support that the use of TST is still reliable and an effective diagnostic method for the detection of LTBI in anti-TNF therapy.

Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry

“…25,26 LTBI was diagnosed by TST in 13Á4% of patients with rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis) undergoing treatment with infliximab in Spain. 27 The clinical implications of diagnosing LTBI are very important.…”

Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up

“…Latent tuberculosis infection reactivation is of special concern with the use of tumour necrosis factor inhibitors [31], and the risk seems to be higher with monoclonal antibodies than with etanercept in patients with rheumatoid arthritis [32,33]. In our study, 8 patients showed a positive reaction only after a second TST procedure, indicating that a 2-step TST may be helpful for the detection of latent tuberculosis prior to a course of biological therapy in certain patient populations [21] despite negative results of TST and/or γ-interferon release assays.…”

“…Before treatment, a chest X-ray and a tuberculin skin test (TST) with protein-purified derivative were performed to rule out latent tuberculosis. In patients with negative TST results, the TST was repeated to rule out false-negative results due to potential immunosuppression [21]. Follow-up data (physical examination, vital signs and laboratory tests, disease activity, observed AEs, and concomitant used drugs) were collected every 3 months.…”

Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy

“…Recent epidemiological studies reported a prevalence rate of LTBI in patients with psoriasis of 5-22% in Italy, 11-14 10% in London, 28 11% in Taiwan 29 and 20-29% in Spain, which is a highprevalence country for tuberculosis. 30,31 LTBI was diagnosed using TST in 13Á4% of patients with rheumatic diseases (RA, ankylosing spondylitis and PsA) undergoing treatment with infliximab in Spain. 32 The present study showed some fluctuations of QFT-GIT results between baseline and follow-up at month 31 AE 1Á7.…”